Skip to content
10-K

Annual Report

CytomX Therapeutics, Inc. CTMX

0001193125-26-107146

← back to feed
Filed
Mar 16, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 137.94M sh
Shares Diluted FY 2025 · Dec 31, 2024 84.75M sh
Shares Outstanding FY 2025 · Dec 31, 2025 170.19M sh
Capex FY 2025 · Dec 31, 2025 $220K
Capex FY 2025 · Dec 31, 2024 $310K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$75.59M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$86.23M
Cash And Equivalents FY 2025 · Dec 31, 2025 $12.67M
Cash And Equivalents FY 2025 · Dec 31, 2024 $38.05M
Stockholders Equity FY 2025 · Dec 31, 2025 $99.01M
Stockholders Equity FY 2025 · Dec 31, 2024 −$456K
Stockholders Equity FY 2025 · Dec 31, 2023 −$47.45M
Current Liabilities FY 2025 · Dec 31, 2025 $46.62M
Current Liabilities FY 2025 · Dec 31, 2024 $85.77M
Total Liabilities FY 2025 · Dec 31, 2025 $52.56M
Total Liabilities FY 2025 · Dec 31, 2024 $120.99M
Current Assets FY 2025 · Dec 31, 2025 $143.92M
Current Assets FY 2025 · Dec 31, 2024 $107.31M
Total Assets FY 2025 · Dec 31, 2025 $151.57M
Total Assets FY 2025 · Dec 31, 2024 $120.53M
Sga Expense FY 2025 · Dec 31, 2025 $29.84M
Sga Expense FY 2025 · Dec 31, 2024 $29.73M
Rd Expense FY 2025 · Dec 31, 2025 $68.73M
Rd Expense FY 2025 · Dec 31, 2024 $83.38M
Net Income FY 2025 · Dec 31, 2025 −$17.37M
Net Income FY 2025 · Dec 31, 2024 $31.87M
Operating Income FY 2025 · Dec 31, 2025 −$22.36M
Operating Income FY 2025 · Dec 31, 2024 $25M
Revenue FY 2025 · Dec 31, 2025 $76.2M
Revenue FY 2025 · Dec 31, 2024 $138.1M